The latest article for NPD team 1 has been published this month into the Journal of Neuroinflammation.

Membrane-type matrix metalloproteinase 5 (MT5-MMP) deficiency in the 5xFAD mouse model of Alzheimer's disease reduces brain neuroinflammation along with amyloidosis, and prevents deficits in synaptic activity and cognition in prodromal stages of the disease. In addition, MT5-MMP deficiency prevents interleukin-1 beta (IL-1β)-mediated inflammation in the peripheral nervous system.

Don't miss the next Neuro'binar of NeuroMarseille with Emmanuel Nivet (Team 6) !

Next Tuesday, on March 22nd, 2022, at 1 pm online, discover Dr Emmanuel Nivet's work in the 13th edition of Neuro'binar:

🔘  Emmanuel Nivet (INP) will present his research topic entitled: "Human induced pluripotent stem cells to study the role of astrocytes in Alzheimer’s disease"

If you want to know more about the treatment of glioblastoma with Gold Nanorods, click on the title "Well-Defined Polyethylene Glycol Microscale Hydrogel Blocks Containing Gold Nanorods for Dual Photothermal and Chemotherapeutic Therapy" , a publication co-authored by Chiara Bastiancich, post-doc in the GlioME team.

Participating in the virtual conference "Tumor Microenvironment Heterogeneity in Cancer Progression: Challenge or Opportunity", Emmanuel Snacel-Fazy, a 2nd year PhD student in the GlioME team won the prize for the best presentation on the "Remodeling of the glioblstoma immune landscape by smac mimetic GDC-0152".

On February 22nd at 1 pm don't miss the next Neurobinar of NeuroMarseille !

Within the cycle M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research, on January 17 Michel Khrestchatisky (CNRS Research Director, Director of the Institute for Neurophysiopathology) Co-Founder & Scientific Counsel of Vect-Horus presented the conference entitled “"Development of molecular vectors for targeted delivery of RNAi via receptor-mediated transport".

Vect-Horus annonce l’accord de la Région SUD Provence-Alpes-Côte d’Azur, responsable de la mise en œuvre du dispositif REACT-EU dans le cadre du Programme Opérationnel FEDER-FSE, pour une subvention de plus d’un million d’euros. Ce projet est financé avec le concours de l’Union européenne avec le Fonds Européen de Développement Régional.

Pour plus d' information, lisez l'article complet dans BUSINESS WIRE.

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study